Amgen (BUE:AMGN) Accounts Payable & Accrued Expense : ARS5,620,048 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Amgen Accounts Payable & Accrued Expense?

Amgen's quarterly accounts payable & accrued expense increased from Jun. 2023 (ARS3,583,200 Mil) to Sep. 2023 (ARS5,433,324 Mil) and increased from Sep. 2023 (ARS5,433,324 Mil) to Dec. 2023 (ARS5,620,048 Mil).

Amgen's annual accounts payable & accrued expense increased from Dec. 2021 (ARS1,057,769 Mil) to Dec. 2022 (ARS2,178,947 Mil) and increased from Dec. 2022 (ARS2,178,947 Mil) to Dec. 2023 (ARS5,620,048 Mil).

Amgen Accounts Payable & Accrued Expense Historical Data

The historical data trend for Amgen's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Accounts Payable & Accrued Expense Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

498,332.50

812,986.17

1,057,769.24

2,178,946.99

5,620,048.01

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2,178,946.99	2,643,416.61	3,583,199.97	5,433,323.85	5,620,048.01

Amgen Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.